Breast Cancer Breakthroughs Episode 16: On the Horizon of PI3K Pathway Inhibition

The PI3 Kinase pathway plays a key role in breast cancer, but there have been challenges targeting it. In the next episode of Breast Cancer Breakthroughs, we’ll hear experts talk about this pathway and how new research is ushering in the next generation of PI3K inhibitors. You’ll hear from Komen Scholar Carlos Arteaga, M.D., and medical oncologist Komal Jhaveri, M.D. as they talk about how the PI3 Kinase pathway impacts breast cancer, the challenges in targeting this pathway, and some recent developments from clinical trials that are poised to usher in new treatments to improve patient outcomes while maintaining quality of life. You’ll also hear from Advocate in Science member Thelma Brown as she discusses the hope research provides and the importance of research advancements reaching all impacted populations.

Speakers:
- Kelsey Hampton, PhD, is Director, Mission Communications & Education at Susan G. Komen
- Carlos Arteaga, M.D., is a medical oncologist at the University of Texas Southwestern Medical Center.
- Komal Jhaveri, MD, FACP, is a medical oncologist at Memorial Sloan Kettering Cancer Center.
- Thelma Brown is a Komen Advocate in Science.

Primary Links:
- Sign up for reminders about future episodes of Breast Cancer Breakthroughs here: https://www.komen.org/about-komen/our-impact/breast-cancer/breast-cancer-breakthroughs-series/
- Link to Survey: https://susangkomen.iad1.qualtrics.com/jfe/form/SV_b4pVz10XB2gPJoq
- Clinical Trial Finder: https://www.breastcancertrials.org/BCTIncludes/index.html
- Blog- Breast Cancer Breakthroughs Episode 16: On the Horizon of PI3K Pathway Inhibition: https://www.komen.org/blog/bcbt-pi3k-pathway/

Videos:
- Mutations and Breast Cancer: https://www.youtube.com/watch?v=Ub6BqXbDeHY
- Breast Cancer Breakthroughs -A Window into Breast Cancer Through a Blood Test: https://www.youtube.com/watch?v=GUdRsV_gdwM

Additional Resources:
- PI3 Kinase and AKT Inhibitors for Metastatic Breast Cancer: https://www.komen.org/breast-cancer/metastatic/metastatic/pi3-kinase-inhibitors-for-metastatic-breast-cancer/
- mTOR Inhibitors for Metastatic Breast Cancer: https://www.komen.org/breast-cancer/metastatic/metastatic/mtor-inhibitors-for-metastatic-breast-cancer/
- Emerging Areas in Research on Metastatic Breast Cancer: https://www.komen.org/breast-cancer/metastatic/emerging-areas/
- Shining a Spotlight on the Unmet Needs of Patients with Advanced ER-positive/HER2-negative breast cancer: https://www.komen.org/blog/spotlight-on-er-positive-her2-negative/
- MBC Impact Series: https://www.komen.org/about-komen/our-impact/breast-cancer/metastatic-breast-cancer-impact-series/#about
- Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2830759#google_vignette
- Komen Health Equity Press Release: https://www.komen.org/news/analysis-led-by-susan-g-komenshows-fewer-black-women-dying-from-breast-cancer-in-nine-major-u-s-metro-areas/

Clinical Trials Mentioned in Episode:
- Re-Discover 2 (Active, recruiting, NCT06982521): https://clinicaltrials.gov/study/NCT06982521
- VIKTORIA-1 (Active, recruiting) NCT05501886: https://www.clinicaltrials.gov/study/NCT05501886
- VIKTORIA-2 (Active, recruiting) NCT06757634: https://clinicaltrials.gov/study/NCT06757634?term=VIKTORIA-2&rank=1
- INAVO120 (Active, not recruiting) NCT04191499: https://clinicaltrials.gov/study/NCT04191499?term=inavo120&rank=1

00:00 Introduction
01:07 Background on the PI3K Pathway
02:11 Progress and Perils of Targeting the PI3K Pathway in Breast Cancer
05:20 Clinical Trials to Expand Targeted Therapies for PI3K Pathway Inhibition
10:50 Disparities Observed in PI3K Pathway Targeted Therapies
14:28 Conclusion